IWAA 2021 23rd Annual Scientific Session

September 23, 2021 to September 25, 2021

This activity is designed to allow learners to continue exploring the immunology frontier.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and Intermountain West Allergy Association (IWAA).  The American College of Allergy, Asthma and Immunology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The American College of Allergy, Asthma & Immunology designates this live activity for a maximum of  13 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Target Audience

Practicing allergists
Allied health professionals

Learning Objectives

Upon completion of this activity the participant should be able to:

1. Summarize recent data, expert opinion and clinical practice guidelines on the treatment of allergic and immunological disease.    
2  Describe the safety and efficacy profiles of established and emerging therapies for the treatment of allergic and immunological diseases.
3. Apply knowledge of the pathophysiology of allergic and immunological diseases to clinical decision-making. 

    Additional information

    As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines an “ineligible company” as companies whose primary business is producing, marketing, re-selling, or distributing health care goods or services, used by or on patients. Examples of such organizations include:

    Ambulatory procedure centers
    Blood banks
    Diagnostic labs that do not sell proprietary products
    Electronic health records companies
    Government or military agencies
    Group medical practices
    Health law firms
    Health profession membership organizations
    Hospitals or healthcare delivery systems
    Infusion centers
    Insurance or managed care companies
    Nursing homes
    Pharmacies that do not manufacture proprietary compounds
    Publishing or education companies
    Rehabilitation centers
    Schools of medicine or health science universities
    Software or game developers

    The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

    Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

    Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All identified conflicts of interest have been mitigated.

    Course summary
    Available credit: 
    • 14.50 AMA PRA Category 1 Credit™
    • 14.50 Attendance
    Course opens: 
    Course expires: 
    Event starts: 
    09/23/2021 - 4:30pm CDT
    Event ends: 
    09/25/2021 - 5:15pm CDT

    Jonathan Bernstein, M.D.
    Advisor, Speaker, Ind Contractor – AstraZeneca, Genentech, Novartis, Sanofi Regeneron Speaker, Ind Contractor – GSK

    Carla Davis, M.D.
    Researcher – Allergenis, DBV Technologies, Therapeutics, Nestle, Inc, Regeneron 

    Matthew Greenhawt, M.D.    
    Advisor – ALK-Abello, AllerGenis, Allergy Therapeutics, Aravax, DBV, Genentech, GSK, Merck, Novartis, Nutricia, Pfizer, Prota, Sanofi, USWorldMeds,
    Advisor, Speaker – Aquestive

    Melinda Rathkopf, M.D.    
    Speaker – Teva

    Andrew White, M.D.
    Advisor – ALK, Blueprint Pharmaceuticals, Genentech
    Advisor, Speaker – AstraZeneca, GSK, Optinose, Sanofi/Regeneron

    Carl Thornblade, M.D.    
    Contracted Research – AstraZeneca, Bayer, Bellus, Bond Avillion 2 Development, Galderma, Leo Pharma, Novartis, Regeneron, Sanofi-Aventis, Satsuma, Shionogi, Teva, Verona

    The following have no relevant financial relationships to disclose:
    Ronald England, M.D.    
    Richard Henry, M.D.    
    Doug Huneywell    
    John Kelso, M.D.    
    Jennifer Kuehn, CPC    
    Karina Serban, M.D.    
    Carl Thornblade, M.D.
    Jim Thompson, Ph.D.    
    Gregory Wickern, M.D.

    Available Credit

    • 14.50 AMA PRA Category 1 Credit™
    • 14.50 Attendance
    Please login or create an account to take this course.